Of note, improved antigen presentation and increased frequency of tumor associated DCs with high expression of CD40, CD80, and CD86 co-stimulatory molecules have been described in response to olaparib, together with enhanced transition of CD8+ T cells to the tumor site [90]. Here, CD8A is linked to neoplasm.